COMPARISON OF SAFETY AND EFFICACY OF RIVAROXABAN AND ENOXAPARIN FOR TREATMENT OF CANCER ASSOCIATED VENOUS THROMBOEMBOLISM

RAA KHAN; AI MASOOD; A SAFDAR; A MANAN

doi:10.54112/bcsrj.v2023i1.242

Authors

RAA KHAN Department of Oncology, Nishter medical university, and Hospital, (NMU & H) Multan, Pakistan
AI MASOOD Department of Radiation Oncology, Nishter medical university, and Hospital, (NMU & H) Multan, Pakistan
A SAFDAR Department of Oncology, Nishter medical university, and Hospital, (NMU & H) Multan, Pakistan
A MANAN Department of Oncology, Nishter medical university, and Hospital, (NMU & H) Multan, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2023i1.242

Keywords:

anticoagulation, enoxaparin, Rivaroxaban, venous thromboembolism, Malignancy

Abstract

The retrospective study was conducted in Nishtar Medical Hospital from January 2022 to January 2023 to compare the safety and efficacy of Rivaroxaban with low molecular weight heparin (LMWH) such as enoxaparin for the treatment of cancer-associated venous thromboembolism (VTE). A total of 250 patients were included in the study. The participants were divided into a control group (who received LMWH (enoxaparin)) and a study group (who received Rivaroxaban). The primary outcome was the occurrence of symptomatic VTE and major bleeding events during the follow-up period. After 3 months, VTE recurred in 1 (1.6%) patient in the rivaroxaban group and 6 (3.1%) patients in the enoxaparin group. After 3 months, Rivaroxaban had 4 (6.6%), and the enoxaparin group had 5 (2.6%) major bleeding events. During the 3 to 12-month period, there was no significant difference regarding treatment outcomes in groups. Based on the results, we can conclude from this study that Rivaroxaban offers effective therapy for cancer-associated VTE, but its bleeding complications are higher than LMWH.

Downloads

Download data is not yet available.

References

Ageno, W., Barni, S., Di Nisio, M., Falanga, A., Imberti, D., Labianca, R. F., and Mantovani, L. (2019). Treatment of venous thromboembolism with tinzaparin in oncological patients. Minerva Medica 110, 251-258.

Bates, S. M., Rajasekhar, A., Middeldorp, S., McLintock, C., Rodger, M. A., James, A. H., Vazquez, S. R., Greer, I. A., Riva, J. J., and Bhatt, M. (2018). American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood advances 2, 3317-3359.

Elsebaie, M. A., van Es, N., Langston, A., Büller, H. R., and Gaddh, M. (2019). Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta‐analysis. Journal of Thrombosis and Haemostasis 17, 645-656.

Espitia, O., Douane, F., Hersant, J., Abbadie, F., Sobocinski, J., Heautot, J.-F., Miossec, A., Lapébie, F.-X., Hartung, O., and Thouveny, F. (2023). Predictive factors of stent patency in iliofemoral venous diseases in a multicenter cohort study. European Journal of Vascular and Endovascular Surgery.

Htut, T. W., Thein, K. Z., Aung, K. L., and Oo, T. H. (2022). Primary ambulatory thromboprophylaxis in patients with pancreatic cancer receiving chemotherapy: hope or hype? Supportive Care in Cancer 30, 8511-8517.

Iorga, R. A., Bratu, O. G., Marcu, R. D., Constantin, T., Mischianu, D. L. D., Socea, B., Gaman, M. A., and Diaconu, C. C. (2019). Venous thromboembolism in cancer patients: Still looking for answers. Experimental and therapeutic medicine 18, 5026-5032.

Lee, A. Y., Kamphuisen, P. W., Meyer, G., Bauersachs, R., Janas, M. S., Jarner, M. F., Khorana, A. A., and Investigators, C. (2015). Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. Jama 314, 677-686.

Mokadem, M. E., Hassan, A., and Algaby, A. Z. (2021). Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular 29, 745-750.

Paul, J. D., and Cifu, A. S. (2019). Prevention and management of venous thromboembolism. JAMA 322, 1602-1603.

Pignataro, B. S., Nishinari, K., Cavalcante, R. N., Centofanti, G., Yazbek, G., Krutman, M., Bomfim, G. A. Z., Fonseca, I. Y. I., Teivelis, M. P., and Wolosker, N. (2017). Oral rivaroxaban for the treatment of symptomatic venous thromboembolism in 400 patients with active cancer: a single-center experience. Clinical and Applied Thrombosis/Hemostasis 23, 883-887.

Raskob, G. E., van Es, N., Verhamme, P., Carrier, M., Di Nisio, M., Garcia, D., Grosso, M. A., Kakkar, A. K., Kovacs, M. J., and Mercuri, M. F. (2018). Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine 378, 615-624.

Raskob, G. E., Van Es, N., Verhamme, P., Carrier, M., Di Nisio, M., Garcia, D. A., Grosso, M. A., Kakkar, A. K., Kovacs, M. J., and Mercuri, M. F. (2017). A randomized, open-label, blinded outcome assessment trial evaluating the efficacy and safety of LMWH/edoxaban versus dalteparin for venous thromboembolism associated with cancer: Hokusai VTE-Cancer Study. Blood 130, LBA-6.

Sabatino, J., De Rosa, S., Polimeni, A., Sorrentino, S., and Indolfi, C. (2020). Direct oral anticoagulants in patients with active cancer: a systematic review and meta-analysis. Cardio Oncology 2, 428-440.

Sidahmed, S., Abdalla, A., Kheiri, B., Bala, A., Salih, M., Bachuwa, G., Kafri, Z., Kuderer, N. M., and Lyman, G. H. (2020). Anticoagulants for the treatment of venous thromboembolism in patients with cancer: A comprehensive systematic review, pairwise and network meta-analysis. Critical Reviews in Oncology/Hematology 152, 103005.

Stevens, S. M., Woller, S. C., Kreuziger, L. B., Bounameaux, H., Doerschug, K., Geersing, G.-J., Huisman, M. V., Kearon, C., King, C. S., and Knighton, A. J. (2021a). Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest 160, e545-e608.

Stevens, S. M., Woller, S. C., Kreuziger, L. B., Bounameaux, H., Doerschug, K., Geersing, G.-J., Huisman, M. V., Kearon, C., King, C. S., and Knighton, A. J. (2021b). Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest 160, 2247-2259.

van Hout, B., Hawe, E., and Cohen, A. T. (2020). Impact of Patient Characteristics on Treatment Outcomes in Symptomatic Venous Thromboembolism: Results of HOKUSAI-VTE Randomized Trial Analysis. TH Open 4, e245-e254.

1056/NEJMoa1711948